HepaRegeniX will present interim Phase 1b data suggesting darizmetinib, an oral MKK4 inhibitor, may accelerate liver regeneration after hepatectomy in colorectal cancer patients.
Key Takeaways
- Darizmetinib is described as an oral small-molecule inhibitor of MKK4 that stabilizes.
- HepaRegeniX announced that an abstract reporting interim Phase 1b data for darizmetinib (HRX215).
- New data highlights how darizmetinib may help the liver regrow after surgery.